{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:08:56Z","timestamp":1785150536361,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Canadian Network and Centre for Trials International"},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.cjca.2019.04.026","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T10:06:13Z","timestamp":1557309973000},"page":"1377-1385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2613-9142","authenticated-orcid":false,"given":"Robert C.","family":"Welsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-9956","authenticated-orcid":false,"given":"Robinder S.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahar","family":"Lavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasko","family":"Kedev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren J.","family":"Cantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6001-9534","authenticated-orcid":false,"given":"Vladim\u00edr","family":"D\u017eav\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2329-2504","authenticated-orcid":false,"given":"Sanjit S.","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2019.04.026_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.04.026_bib2","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.04.026_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.04.026_bib4","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.04.026_bib5","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jacc.2011.06.044","volume":"58","author":"Patti","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.04.026_bib6","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.04.026_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2019.04.026_bib8","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.04.026_bib9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.acvd.2013.06.055","article-title":"Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects","volume":"106","author":"Mao","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2019.04.026_bib10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.04.026_bib11","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.04.026_bib12","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.04.026_bib13","first-page":"214","article-title":"2018 Canadian Cardiovascular Society\/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy","volume":"34","author":"Mehta","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2019.04.026_bib14","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMoa1415098","article-title":"Randomized trial of primary PCI with or without routine manual thrombectomy","volume":"372","author":"Jolly","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.04.026_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ahj.2013.12.002","article-title":"Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI","volume":"167","author":"Jolly","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2019.04.026_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(15)00448-1","article-title":"Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial","volume":"387","author":"Jolly","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.04.026_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/FJC.0000000000000459","article-title":"Efficacy and safety of novel oral P2Y12 receptor inhibitors in patients with ST-segment elevation myocardial infarction undergoing PCI, a systematic review and meta-analysis","volume":"69","author":"Sun","year":"2017","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2019.04.026_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.carrev.2016.10.005","article-title":"A\u00a0comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: a network meta-analysis","volume":"18","author":"Westman","year":"2017","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.cjca.2019.04.026_bib19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jcin.2016.02.013","article-title":"Optimal P2Y12 inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a network meta-analysis","volume":"9","author":"Rafique","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2019.04.026_bib20","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1161\/CIRCULATIONAHA.116.024823","article-title":"Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study","volume":"134","author":"Motovska","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.04.026_bib21","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.04.026_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","article-title":"Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile","volume":"25","author":"Jakubowski","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.cjca.2019.04.026_bib23","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.04.026_bib24","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.04.026_bib25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2019.04.026_bib26","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.bbamem.2010.11.016","article-title":"Adenosine and its receptors in the heart: regulation, retaliation and adaptation","volume":"1808","author":"Headrick","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cjca.2019.04.026_bib27","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.101.18.2154","article-title":"Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction","volume":"101","author":"Marzilli","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.04.026_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1074248411410883","article-title":"Ticagrelor inhibits adenosine uptake in\u00a0vitro and enhances adenosine-mediated hyperemia responses in a canine model","volume":"17","author":"van Giezen","year":"2012","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cjca.2019.04.026_bib29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacc.2012.11.032","article-title":"Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans","volume":"61","author":"Wittfeldt","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.04.026_bib30","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2017.02.048","article-title":"Effect of ticagrelor versus clopidogrel on vascular reactivity","volume":"69","author":"Alemayehu","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.04.026_bib31","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.04.026_bib32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.04.026_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12265-013-9527-3","volume":"7","author":"Schulz","year":"2014","journal-title":"J\u00a0Cardiovasc Transl Res"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X19303009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X19303009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:41:42Z","timestamp":1760107302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X19303009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0828282X19303009"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2019.04.026","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2019.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}